Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec has expanded its collaboration with Harvard University, with the second strategic alliance to discover and develop new biomarkers and treatments pertaining to kidney disease.
Subscribe to our email newsletter
The alliance also includes Brigham and Women’s Hospital.
The deal will focus on kidney biology, physiology and disease along with a set of tools to identify, validate and develop candidate targets and biomarkers.
The program ‘CureNephron’ intends to deliver and exploit novel therapeutic targets as well as biomarkers that allow more accurate diagnosis, monitoring and treatment of chronic and acute kidney disease.
Furthermore, the agreement will implement systematic and unbiased approaches towards the identification of kidney disease relevant mechanisms with emphasis on mechanisms with disease modifying potential.